Concepedia

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

Yi‐Long Wu, Shun Lü, You Lü, Jianying Zhou, Yuankai Shi, Virote Sriuranpong, Chun‐Ming Tsai, Chin‐Hee Chung, Keith D. Wilner, Yiyun Tang,

Journal of Thoracic Oncology · 2018 · 185 citations · 15 references

Concepts

MedicineOncologyPharmacologyCancer PharmacologyChemotherapyOncology PharmacotherapyCancer Survival AnalysisLung CancerLung Cancer PharmacotherapyAlk InhibitionAnaplastic Lymphoma Kinase InhibitorsArea Under The Concentration - Time CurveArea Under The Plasma Concentration-time CurveNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPlatinum-based RegimensReceptor Tyrosine Kinase Gene Amplification

References

15

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 16K citations

Pharmacy, Oncology, Cancer Symptom Management +15

EuroQol - a new facility for the measurement of health-related quality of life

Health Policy · 1990 · 15.8K citations

Pharmacy, Health Sciences, Health Assessment +11

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations

Medicine, Molecular Biology, Oncology +14

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Medicine, Oncology, Pharmacology +15